API | ascrinvacumab

ascrinvacumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank

Active Ingredient History

NOW

Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
ascrinvacumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Serine/threonine-protein kinase receptor R3 (Homo sapiens) ^UniProt
- Serine/threonine-protein kinase receptor R3 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

ascrinvacumab | pf03446962 | pf-03446962

Organizations (7)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Carcinoma, Hepatocellular (Phase 2)

Colorectal Neoplasms (Phase 1)

Drug Misuse (Phase 1/Phase 2)

Mesothelioma, Malignant (Phase 2)

Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue